David Miller to Lung Neoplasms
This is a "connection" page, showing publications David Miller has written about Lung Neoplasms.
Connection Strength
3.962
-
Eberth JM, Zgodic A, Pelland SC, Wang SY, Miller DP. Outcomes of Shared Decision-Making for Low-Dose Screening for Lung Cancer in an Academic Medical Center. J Cancer Educ. 2023 Apr; 38(2):522-537.
Score: 0.644
-
Bellinger C, Pinsky P, Foley K, Case D, Dharod A, Miller D. Lung Cancer Screening Benefits and Harms Stratified by Patient Risk: Information to Improve Patient Decision Aids. Ann Am Thorac Soc. 2019 04; 16(4):512-514.
Score: 0.520
-
Dharod A, Bellinger C, Foley K, Case LD, Miller D. The Reach and Feasibility of an Interactive Lung Cancer Screening Decision Aid Delivered by Patient Portal. Appl Clin Inform. 2019 01; 10(1):19-27.
Score: 0.512
-
Pinsky PF, Bellinger CR, Miller DP. False-positive screens and lung cancer risk in the National Lung Screening Trial: Implications for shared decision-making. J Med Screen. 2018 06; 25(2):110-112.
Score: 0.468
-
Miller DP, Reuland DS. Controversies in cancer screening. N C Med J. 2014 Jul-Aug; 75(4):253-6.
Score: 0.374
-
Miller DP, Neuberg D, de Vivo I, Wain JC, Lynch TJ, Su L, Christiani DC. Smoking and the risk of lung cancer: susceptibility with GSTP1 polymorphisms. Epidemiology. 2003 Sep; 14(5):545-51.
Score: 0.177
-
Miller DP, De Vivo I, Neuberg D, Wain JC, Lynch TJ, Su L, Christiani DC. Association between self-reported environmental tobacco smoke exposure and lung cancer: modification by GSTP1 polymorphism. Int J Cancer. 2003 May 10; 104(6):758-63.
Score: 0.173
-
Foley KL, Dressler EV, Weaver KE, Sutfin EL, Miller DP, Bellinger C, Kittel C, Stone RJ, Petty WJ, Land SR, Spangler JG, Lesser GJ, Chiles C. The Optimizing Lung Screening Trial (WF-20817CD): Multicenter Randomized Effectiveness Implementation Trial to Increase Tobacco Use Cessation for Individuals Undergoing Lung Screening. Chest. 2023 Aug; 164(2):531-543.
Score: 0.171
-
Bellinger C, Foley KL, Dressler EV, Kittel C, Miller DP, Weaver KE, Sutfin EL, Petty WJ, Spangler J, Stone R, Anderson DM, Kehn H, Steenstra C, Panikkar R, Chiles C. Organizational Characteristics and Smoking Cessation Support in Community-Based Lung Cancer Screening Programs. J Am Coll Radiol. 2022 Apr; 19(4):529-533.
Score: 0.159
-
Zgodic A, Zahnd WE, Miller DP, Studts JL, Eberth JM. Predictors of Lung Cancer Screening Utilization in a Population-Based Survey. J Am Coll Radiol. 2020 Dec; 17(12):1591-1601.
Score: 0.142
-
Lewis JA, Petty WJ, Tooze JA, Miller DP, Chiles C, Miller AA, Bellinger C, Weaver KE. Low-Dose CT Lung Cancer Screening Practices and Attitudes among Primary Care Providers at an Academic Medical Center. Cancer Epidemiol Biomarkers Prev. 2015 Apr; 24(4):664-70.
Score: 0.097
-
Asomaning K, Miller DP, Liu G, Wain JC, Lynch TJ, Su L, Christiani DC. Second hand smoke, age of exposure and lung cancer risk. Lung Cancer. 2008 Jul; 61(1):13-20.
Score: 0.060
-
Bradbury PA, Heist RS, Kulke MH, Zhou W, Marshall AL, Miller DP, Su L, Park S, Temel J, Fidias P, Sequist L, Lynch TJ, Wain JC, Shepherd FA, Christiani DC, Liu G. A rapid outcomes ascertainment system improves the quality of prognostic and pharmacogenetic outcomes from observational studies. Cancer Epidemiol Biomarkers Prev. 2008 Jan; 17(1):204-11.
Score: 0.060
-
Zhou W, Heist RS, Liu G, Asomaning K, Miller DP, Neuberg DS, Wain JC, Lynch TJ, Christiani DC. Second hand smoke exposure and survival in early-stage non-small-cell lung cancer patients. Clin Cancer Res. 2006 Dec 01; 12(23):7187-93.
Score: 0.055
-
Zhou W, Park S, Liu G, Miller DP, Wang LI, Pothier L, Wain JC, Lynch TJ, Giovannucci E, Christiani DC. Dietary iron, zinc, and calcium and the risk of lung cancer. Epidemiology. 2005 Nov; 16(6):772-9.
Score: 0.051
-
Thurston SW, Liu G, Miller DP, Christiani DC. Modeling lung cancer risk in case-control studies using a new dose metric of smoking. Cancer Epidemiol Biomarkers Prev. 2005 Oct; 14(10):2296-302.
Score: 0.051
-
Liu G, Zhou W, Wang LI, Park S, Miller DP, Xu LL, Wain JC, Lynch TJ, Su L, Christiani DC. MPO and SOD2 polymorphisms, gender, and the risk of non-small cell lung carcinoma. Cancer Lett. 2004 Oct 08; 214(1):69-79.
Score: 0.048
-
Zhou W, Liu G, Miller DP, Thurston SW, Xu LL, Wain JC, Lynch TJ, Su L, Christiani DC. Polymorphisms in the DNA repair genes XRCC1 and ERCC2, smoking, and lung cancer risk. Cancer Epidemiol Biomarkers Prev. 2003 Apr; 12(4):359-65.
Score: 0.043
-
Su L, Liu G, Zhou W, Xu LL, Miller DP, Park S, Lynch TJ, Wain JC, Christiani DC. No association between the p21 codon 31 serine-arginine polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev. 2003 Feb; 12(2):174-5.
Score: 0.042
-
Xu LL, Liu G, Miller DP, Zhou W, Lynch TJ, Wain JC, Su L, Christiani DC. Counterpoint: the myeloperoxidase -463G-->a polymorphism does not decrease lung cancer susceptibility in Caucasians. Cancer Epidemiol Biomarkers Prev. 2002 Dec; 11(12):1555-9.
Score: 0.042
-
Zhou W, Liu G, Thurston SW, Xu LL, Miller DP, Wain JC, Lynch TJ, Su L, Christiani DC. Genetic polymorphisms in N-acetyltransferase-2 and microsomal epoxide hydrolase, cumulative cigarette smoking, and lung cancer. Cancer Epidemiol Biomarkers Prev. 2002 Jan; 11(1):15-21.
Score: 0.039
-
Patel N, Miller DP, Snavely AC, Bellinger C, Foley KL, Case D, McDonald ML, Masmoudi YR, Dharod A. A Comparison of Smoking History in the Electronic Health Record With Self-Report. Am J Prev Med. 2020 04; 58(4):591-595.
Score: 0.034